ABBOTT LABORATORIES XBRL Taxonomy Presentation Networks

-Network: (0010 - Statement - Condensed Consolidated Statement of Earnings)
-Statement of Earnings {ID1}
Net Sales {ID2}
Cost of products sold {ID3}
Research and development {ID4}
Acquired in-process research and development {ID5}
Selling, general and administrative {ID6}
Total Operating Cost and Expenses {ID7}
Operating Earnings {ID8}
Interest expense {ID9}
Interest (income) {ID10}
(Income) from TAP Pharmaceutical Products Inc. joint venture {ID11}
Net foreign exchange loss (gain) {ID12}
Other (income) expense, net {ID13}
Earnings Before Taxes {ID14}
Taxes on Earnings {ID15}
Net Earnings {ID16}
Basic Earnings Per Common Share (in dollars per share) {ID17}
Diluted Earnings Per Common Share (in dollars per share) {ID18}
Cash Dividends Declared Per Common Share (in dollars per share) {ID19}
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) {ID20}
Dilutive Common Stock Options and Awards (in shares) {ID21}
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options and Awards (in shares) {ID22}
Outstanding Common Stock Options Having No Dilutive Effect (in shares) {ID23}
-Network: (0020 - Statement - Condensed Consolidated Statement of Cash Flows)
-Statement of Cash Flows {ID24}
-Cash Flow From (Used in) Operating Activities {ID25}
Net earnings {ID26}
-Adjustments to reconcile earnings to net cash from operating activities - {ID27}
Depreciation {ID28}
Amortization of intangible assets {ID29}
Share-based compensation {ID30}
Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture {ID31}
Gain on dissolution of TAP Pharmaceutical Products Inc. joint venture {ID32}
Acquired in-process research and development {ID33}
Trade receivables {ID34}
Inventories {ID35}
Other, net {ID36}
Net Cash From Operating Activities {ID37}
-Cash Flow From (Used in) Investing Activities {ID38}
Acquisitions of property and equipment {ID39}
Acquisitions of businesses, net of cash acquired {ID40}
Proceeds from sales of Boston Scientific common stock {ID41}
Purchases of other investment securities, net {ID42}
Other, net {ID43}
Net Cash (Used in) Investing Activities {ID44}
-Cash Flow From (Used in) Financing Activities {ID45}
Proceeds from issuance of short-term debt and other {ID46}
Proceeds from issuance of long-term debt {ID47}
Repayments of long-term debt {ID48}
Purchases of common shares {ID49}
Proceeds from stock options exercised, including tax benefit {ID50}
Dividends paid {ID51}
Net Cash From (Used in) Financing Activities {ID52}
Effect of exchange rate changes on cash and cash equivalents {ID53}
Net Increase in Cash and Cash Equivalents {ID54}
Cash and Cash Equivalents, Beginning of Year {ID55}
Cash and Cash Equivalents, End of Period {ID56}
-Network: (0030 - Statement - Condensed Consolidated Balance Sheet)
-Balance Sheet {ID57}
-Assets {ID58}
-Current Assets {ID59}
Cash and cash equivalents {ID60}
Investments, primarily time deposits and certificates of deposit {ID61}
Trade receivables, less allowances of $299,234 in 2009 and $263,632 in 2008 {ID62}
-Inventories: {ID63}
Finished products {ID64}
Work in process {ID65}
Materials {ID66}
Total inventories {ID67}
Prepaid expenses, deferred income taxes, and other receivables {ID68}
Total Current Assets {ID69}
Investments {ID70}
Property and Equipment, at Cost {ID71}
Less: accumulated depreciation and amortization {ID72}
Net Property and Equipment {ID73}
Intangible Assets, net of amortization {ID74}
Goodwill {ID75}
Deferred Income Taxes and Other Assets {ID76}
Total Assets {ID77}
-Liabilities and Shareholders' Investment {ID78}
-Current Liabilities: {ID79}
Short-term borrowings {ID80}
Trade accounts payable {ID81}
Salaries, dividends payable, and other accruals {ID82}
Income taxes payable {ID83}
Obligation in connection with conclusion of TAP Pharmaceutical Products, Inc. joint venture {ID84}
Current portion of long-term debt {ID85}
Total Current Liabilities {ID86}
Long-term Debt {ID87}
Post-employment Obligations and Other Long-term Liabilities {ID88}
Commitments and Contingencies {ID89}
-Shareholders' Investment: {ID90}
Preferred shares, one dollar par value; Authorized - 1,000,000 shares, none issued {ID91}
Common shares, without par value; Authorized - 2,400,000,000 shares; Issued at stated capital amount - Shares: 2009: 1,607,948,710; 2008: 1,601,580,899 {ID92}
Common shares held in treasury, at cost - Shares: 2009: 62,036,267; 2008: 49,147,968 {ID93}
Earnings employed in the business {ID94}
Accumulated other comprehensive income (loss) {ID95}
Total Abbott Shareholders' Investment {ID96}
Noncontrolling Interests in Subsidiaries {ID97}
Total Equity {ID98}
Total Liabilities and Shareholders' Equity {ID99}
-Network: (0035 - Statement - Condensed Consolidated Balance Sheet Parenthetical)
-Balance Sheet {ID100}
Trade receivables allowances of $314,325 in 2009 and $263,632 in 2008 (in dollars) {ID101}
Preferred shares authorized (in shares) {ID102}
Preferred shares issued (in shares) {ID103}
Common shares authorized (in shares) {ID104}
Common shares issued (in shares) {ID105}
Common shares held in treasury (in shares) {ID106}
-Network: (1010 - Notes - Basis of Presentation)
-Notes to Financial Statements {ID107}
Basis of Presentation {ID108}
-Network: (1020 - Notes - Supplemental Financial Information)
-Notes to Financial Statements {ID109}
Supplemental Financial Information {ID110}
-Network: (1030 - Notes - Taxes on Earnings)
-Notes to Financial Statements {ID111}
Taxes on Earnings {ID112}
-Network: (1040 - Notes - Litigation and Environmental Matters)
-Notes to Financial Statements {ID113}
Litigation and Environmental Matters {ID114}
-Network: (1050 - Notes - Post-Employment Benefits)
-Notes to Financial Statements {ID115}
Post-Employment Benefits {ID116}
-Network: (1060 - Notes - Comprehensive Income, net of tax)
-Notes to Financial Statements {ID117}
Comprehensive Income, net of tax {ID118}
-Network: (1070 - Notes - Segment Information)
-Notes to Financial Statements {ID119}
Segment Information {ID120}
-Network: (1080 - Notes - Incentive Stock Program)
-Notes to Financial Statements {ID121}
Incentive Stock Program {ID122}
-Network: (1090 - Notes - Conclusion of TAP Pharmaceutical Products Inc. Joint Venture)
-Notes to Financial Statements {ID123}
Conclusion of TAP Pharmaceutical Products Inc. Joint Venture {ID124}
-Network: (1100 - Notes - Business Acquisitions)
-Notes to Financial Statements {ID125}
Business Acquisitions {ID126}
-Network: (1110 - Notes - Financial Instruments, Derivatives and Fair Value Measures)
-Notes to Financial Statements {ID127}
Financial Instruments, Derivatives and Fair Value Measures {ID128}
-Network: (1120 - Notes - Goodwill and Intangible Assets)
-Notes to Financial Statements {ID129}
Goodwill and Intangible Assets {ID130}
-Network: (1130 - Notes - Restructuring Plans)
-Notes to Financial Statements {ID131}
Restructuring Plans {ID132}
-Network: (1140 - Notes - Subsequent Event - Litigation Settlement)
-Notes to Financial Statements {ID133}
Subsequent Event - Litigation Settlement {ID134}
-Network: (9999 - Other Information - Document and Entity Information)
-Document and Entity Information {ID135}
Document Type {ID136}
Document Period End Date {ID137}
Amendment Flag {ID138}
Amendment Description {ID139}
Entity Registrant Name {ID140}
Entity Central Index Key {ID141}
Entity Current Reporting Status {ID142}
Entity Voluntary Filers {ID143}
Current Fiscal Year End Date {ID144}
Entity Filer Category {ID145}
Entity Well-known Seasoned Issuer {ID146}
Entity Common Stock, Shares Outstanding {ID147}
Entity Public Float {ID148}